Medigene Presents First Results for Automated Manufacturing of T Cell Receptor Engineered T Cells
February 23, 2023 08:00 ET
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the...
Medigene to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
February 22, 2023 10:00 ET
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the...
Medigene to Present at the 6th Annual CAR-TCR Summit Europe in London
February 15, 2023 09:00 ET
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the...
Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications
February 01, 2023 11:35 ET
|
Medigene AG
MARTINSRIED and MUNICH, Germany, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and...
Medigene Receives $3 Million Milestone Payment from 2seventy bio
January 18, 2023 11:35 ET
|
Medigene AG
Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW TherapeuticsPayment provides further validation of Medigene’s end-to-end platform MARTINSRIED,...
Medigene Announces Strategy and Corporate Update
November 15, 2022 11:35 ET
|
Medigene AG
Company strategy focused on developing differentiated TCR-T therapies from its proprietary “end-to-end” platform to target solid tumors with high unmet needPipeline expansion and acceleration of lead...
Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
January 05, 2021 08:40 ET
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell...
Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers
June 23, 2020 16:46 ET
|
Medigene AG
MDG1021 becomes Medigene’s second proprietary clinical TCR-T candidateClinical trial approval from Dutch regulatory authority Phase I clinical trial in cancer patients suffering from...
Medigene’s PD1-41BB Switch Receptor Enhances TCR-T Cell Activity Towards Solid Tumors
June 22, 2020 09:00 ET
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, June 22, 2020 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1), a clinical stage immuno-oncology company focusing on the development of T cell...
Medigene Provides Results for Fiscal Year 2019 and Outlook
March 26, 2020 06:18 ET
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, March 26, 2020 (GLOBE NEWSWIRE) -- Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T...